Kidney-Liver drug trial halted early – what happened?

NCT ID NCT06939816

Terminated Disease control Sponsor: Enyo Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small Phase 2 study tested two doses of vonafexor, an oral drug, in 10 people with mild-to-moderate chronic kidney disease and suspected MASH (a type of fatty liver disease). The goal was to see if vonafexor could improve kidney function. However, the trial was terminated early, so the results are limited and we cannot draw firm conclusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vonafexor (oral tablets)
What this could lead to: If it had worked, vonafexor might have pointed toward a new way to protect kidney function in people with both kidney disease and fatty liver disease.
What could go wrong: The trial was terminated early with only 10 participants, so we have very little data. It is too early to know if vonafexor is safe or effective for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE STAGE 2 CHRONIC KIDNEY DISEASE, STAGE 3 METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Contacts and locations

Show contact details

Locations

Profil Institut für Stoffwechselforschung GmbH

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.